Literature DB >> 24752479

Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.

Raphaelle Fanciullino1, Severine Mollard, Florian Correard, Sarah Giacometti, Cindy Serdjebi, Athanassios Iliadis, Joseph Ciccolini.   

Abstract

PURPOSE: We have investigated the impact of particle size on the biodistribution, tumor uptake and antiproliferative efficacy of 5-FU-loaded liposomes.
METHODS: Three different batches of pegylated liposomes varying in size (i.e., 70, 120 and 250 nm respectively) were tested. The active compounds encapsulated were an equimolar mix of 5-FU, 2'-deoxyinosine and folinic acid. Liposomes were subsequently tested on the human breast cancer model MDA231 cells, a model previously found to be resistant to 5-FU. In vitro, antiproliferative efficacy and microscopy studies of liposomes uptake were carried out. In vivo, comparative biodistribution and efficacy studies were performed in tumor-bearing mice.
RESULTS: Difference in size did not change in vitro antiproliferative activity. Fluorescence-Microscopy studies showed that liposomes were mainly uptaken by tumor cells through a direct internalization process, regardless of their size. Biodistribution profiles in tumor-bearing mice revealed higher accumulation of small liposomes in tumors throughout time as compared with normal and large liposomes (p < 0.05). Additionally, we observed that the bigger were the tumors, the more vascularised they were and the greater was the difference in accumulation between small and large liposomes. Consequently, in vivo efficacy studies showed at study conclusion that a 68% reduction in tumor size was achieved with small liposomes (p < 0.05), whereas larger liposomes failed to reduce significantly tumor growth. Similarly, at study conclusion a trend towards higher survival-rate in animals treated with smaller liposomes was observed.
CONCLUSION: This study suggests that particle size is critical to achieve higher selectivity and efficacy in experimental oncology, including in resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752479     DOI: 10.1007/s11095-014-1364-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.

Authors:  J Ciccolini; L Peillard; A Evrard; P Cuq; C Aubert; A Pelegrin; P Formento; G Milano; J Catalin
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

Review 2.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

3.  Drug delivery systems: entering the mainstream.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

4.  Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.

Authors:  Kazuhiro Takara; Hiroto Hatakeyama; Golam Kibria; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
Journal:  J Control Release       Date:  2012-06-20       Impact factor: 9.776

5.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.

Authors:  E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

6.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

Review 7.  Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.

Authors:  Theresa M Allen; Wilson W K Cheng; Jennifer I Hare; Kimberley M Laginha
Journal:  Anticancer Agents Med Chem       Date:  2006-11       Impact factor: 2.505

Review 8.  Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs.

Authors:  Raphaelle Fanciullino; Joseph Ciccolini; Gérard Milano
Journal:  Crit Rev Oncol Hematol       Date:  2013-07-18       Impact factor: 6.312

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes.

Authors:  D C Litzinger; A M Buiting; N van Rooijen; L Huang
Journal:  Biochim Biophys Acta       Date:  1994-02-23
View more
  7 in total

1.  Biodistribution and delivery efficiency of unmodified tumor-derived exosomes.

Authors:  Tyson Smyth; Max Kullberg; Noeen Malik; Peter Smith-Jones; Michael W Graner; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2014-12-16       Impact factor: 9.776

Review 2.  Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.

Authors:  Manisit Das; Leaf Huang
Journal:  J Pharmacol Exp Ther       Date:  2018-12-12       Impact factor: 4.030

3.  Cisplatin and oleanolic acid Co-loaded pH-sensitive CaCO3 nanoparticles for synergistic chemotherapy.

Authors:  Muhammad Waseem Khan; Chenming Zou; Said Hassan; Fakhar Ud Din; Mahaman Yacoubou Abdoul Razak; Asif Nawaz; Abdul Wahab; Sudhair Abbas Bangash
Journal:  RSC Adv       Date:  2022-05-16       Impact factor: 4.036

4.  From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.

Authors:  Anne Rodallec; Guillaume Sicard; Sarah Giacometti; Manon Carré; Bertrand Pourroy; Fanny Bouquet; Ariel Savina; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Journal:  Int J Nanomedicine       Date:  2018-10-23

5.  Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles.

Authors:  A Rodallec; C Franco; S Robert; G Sicard; S Giacometti; B Lacarelle; F Bouquet; A Savina; R Lacroix; F Dignat-George; J Ciccolini; P Poncelet; R Fanciullino
Journal:  Sci Rep       Date:  2020-03-05       Impact factor: 4.379

6.  Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Authors:  Anne Rodallec; Jean-Michel Brunel; Sarah Giacometti; Helene Maccario; Florian Correard; Eric Mas; Caroline Orneto; Ariel Savina; Fanny Bouquet; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Journal:  Int J Nanomedicine       Date:  2018-06-18

7.  Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging.

Authors:  Leanne De Silva; Ju-Yen Fu; Thet Thet Htar; Wan Hamirul Bahrin Wan Kamal; Azahari Kasbollah; Saravanan Muniyandy; Lay-Hong Chuah
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.